EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhaled “Muco‐Trapping” Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections

Morgan D McSweeney iD, Sarhad Alnajjar, Alison M Schaefer, Zach Richardson, Whitney Wolf, Ian Stewart, Pun Sriboonyapirat, Justin McCallen, Ellen Farmer, Bernadette Nzati, Sam Lord, Brian Farrer und 7 weitere

Advanced Science · 2024

DOI: 10.1002/advs.202306729 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Morgan D McSweeney und 18 weiteren Autor:innen. Beteiligte Einrichtung: Inhalon Biopharma, Research Triangle Park, NC, 27707, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Respiratory Syncytial Virus Infections. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in infants, the immunocompromised, and the elderly. RSV infects the airway epithelium via the apical membrane and almost exclusively sheds progeny virions back into the airway mucus (AM), making RSV difficult to target by systemically administered therapies. An inhalable “muco‐trapping” variant of motavizumab (Mota‐MT), a potent neutralizing mAb against RSV F is engineered. Mota‐MT traps RSV in AM via polyvalent Fc‐mucin bonds, reducing the fraction of fast‐moving RSV particles in both fresh pediatric and adult AM by ≈20–30‐fold in a Fc‐glycan dependent manner, and facilitates clearance from the airways of mice within minutes. Intranasal dosing of Mota‐MT eliminated viral load in cotton rats within 2 days. Daily nebulized delivery of Mota‐MT to RSV‐infected neonatal lambs, beginning 3 days after infection when viral load is at its maximum, led to a 10 000‐fold and 100 000‐fold reduction in viral load in bronchoalveolar lavage and lung tissues relative to placebo control, respectively. Mota‐MT‐treated lambs exhibited reduced bronchiolitis, neutrophil infiltration, and airway remodeling than lambs receiving placebo or intramuscular palivizumab. The findings underscore inhaled delivery of muco‐trapping mAbs as a promising strategy for the treatment of RSV and other acute respiratory infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalRespiratory Syncytial Virus InfectionsHumansInfantChildAnimalsSheepMiceAgedPalivizumabRespiratory Syncytial VirusesLung

Stichwörter der Autor:innen

RSVmAb nebulizationmonoclonal antibodynebulizationrespiratory syncytial virus

Substanzen

Antibodies, MonoclonalPalivizumab

Autor:innen und Institutionen

  • Inhalon Biopharma, Research Triangle Park, NC, 27707, USA.
  • Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, GU2 7AL, UK.
  • Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina-Chapel Hill, Chapel Hill, NC, 27599, USA.
  • RTI International, Research Triangle Park, NC, 27709, USA.
  • Oregon State University, Corvallis, Oregon, 97331, USA.
  • Department of Anesthesiology, School of Medicine, University of North Carolina, Chapel Hill, NC, 27599, USA.

ORCID-Profile: Morgan D McSweeney, Samuel K Lai

Förderung

  • NIH HHS
  • NIAID NIH HHS
  • NCATS NIH HHS
  • National Institutes of Health
  • David and Lucile Packard Foundation
  • National Science Foundation

Zitieren

APA

McSweeney, M. D., Alnajjar, S., Schaefer, A. M., Richardson, Z., Wolf, W., Stewart, I., Sriboonyapirat, P., McCallen, J., Farmer, E., Nzati, B., Lord, S., Farrer, B., Moench, T. R., Kumar, P. A., Arora, H., Pickles, R. J., Hickey, A. J., Ackermann, M., & Lai, S. K. (2024). Inhaled “Muco‐Trapping” Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections. Advanced Science. https://doi.org/10.1002/advs.202306729

Vancouver

McSweeney MD, Alnajjar S, Schaefer AM, Richardson Z, Wolf W, Stewart I, et al. Inhaled “Muco‐Trapping” Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections. Advanced Science. 2024. doi:10.1002/advs.202306729

BibTeX
@article{McSweeney2024,
  author = {McSweeney, Morgan D and Alnajjar, Sarhad and Schaefer, Alison M and Richardson, Zach and Wolf, Whitney and Stewart, Ian and Sriboonyapirat, Pun and McCallen, Justin and Farmer, Ellen and Nzati, Bernadette and Lord, Sam and Farrer, Brian and Moench, Thomas R and Kumar, Priya A and Arora, Harendra and Pickles, Raymond J and Hickey, Anthony J and Ackermann, Mark and Lai, Samuel K},
  title = {Inhaled “Muco‐Trapping” Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections},
  journal = {Advanced Science},
  year = {2024},
  doi = {10.1002/advs.202306729}
}
Kostenlos starten →